Drug details

Zinbryta (daclizumab for injection)

type of

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

This drug may have the following side effects:

• sore throat
• fever
• depression
• upper respiratory tract infection
• skin rash
• acne
• runny or stuffy nose
• bronchitis
• mouth pain
• swollen lymph nodes
• eczema
• influenza
• rash, including drug rash
• increased alanine aminotransferase (ALT)
• anemia,
  and

The following drugs are related to Zinbryta, either as a replacement or used together:

• Ampyra (dalfampridine extended-release tablets)
• Aubagio (teriflunomide tablets)
• Avonex (interferon beta-1a)
• Copaxone (glatiramer acetate)
• Tecfidera (dimethyl fumarate delayed release capsules)
• Gilenya (fingolimod capsules)
• Tascenso ODT (fingolimod orally disintegrating tablets)
• Rebif (interferon beta-1a)
• Novantrone (mitoxantrone for injection concentrate)
• Tysabri (natalizumab)
• Tyruko (natalizumab-sztn injection)
• Ocrevus (ocrelizumab injection)
• Plegridy (peginterferon beta-1a injection for subcutaneous use)